- Revised label includes Boxed Warning detailing risk of serious skin reactions observed in the post-marketing setting that require treatment discontinuation - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the INCIVEK...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex will webcast its presentation at the 24th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2012 at 12:00 p.m. EST and at the NASDAQ OMX 29th Investor Program on Tuesday, D...

- New Phase 2 data showed approximately 3 of 4 people co-infected with hepatitis C virus (HCV) and HIV achieved HCV viral cure (SVR24) with telaprevir combination treatment - BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new data f...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex will webcast its presentation at the Credit Suisse 2012 Healthcare Conference on Wednesday, November 14, 2012 at 8:00 a.m. MT (10:00 a.m. ET). The presentation will be webcas...

-Companies to evaluate two-drug combination of Vertex's investigational nucleotide analogue VX-135 and GSK's investigational NS5A inhibitor GSK2336805- -Phase 2 proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment regimen- ...

-Company to announce third quarter financial results on Thursday, November 1, 2012- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- As a result of the effects of Hurricane Sandy and the related closure of the financial markets, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced ...

-- Additional KALYDECO™ (ivacaftor) and CF pipeline presentations highlight Vertex's commitment to advancing CF treatment by targeting the underlying cause of the disease -- ORLANDO, Fla.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that ...

	Dutch Version of Press Release	51.1 KB
	Spanish Version of Press Release	59.7 KB
	French Version of Press Release	53.9 KB
	Italian Version of Press Release	18.2 KB
	French Canadian Version of Press Release	130.8 KB
	German Version of Press Release	30.1 KB

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 10 abstracts from its cystic fibrosis (CF) research and development program will be presented at the 26th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Fla., October 11 to 13, 2012. ...

	French Canadian Version	92.7 KB
	French Version	34.2 KB
	German Version	123.1 KB
	Italian Version	118.3 KB
	Spanish Version	118.5 KB

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Yuchun Lee joined its board of directors as an independent director. Mr. Lee was appointed to the class of directors whose term expires in 2013. The Vertex board currently consists of 10 members. ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Stuart A. Arbuckle as Executive Vice President and Chief Commercial Officer. Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at biophar...